Bruker Corporation
Bruker Corporation is a leading global developer and manufacturer of scientific instruments and analytical solutions, and a dominant force in the preclinical imaging market. The company offers one of the broadest portfolios of preclinical imaging systems, which are essential tools for molecular and functional analysis in small animal research. Bruker’s products span multiple modalities, including micro-MRI (Magnetic Resonance Imaging) with high field strengths like the BioSpec series, micro-CT (Computed Tomography) exemplified by the high-resolution SkyScan systems, and hybrid systems like PET/SPECT/CT trimodality imagers. Bruker’s strategy involves continuous innovation and expansion, such as the acquisition of Spectral Instruments Imaging to strengthen its optical imaging offerings. The company’s focus on high-resolution, multi-modality platforms and advanced analysis software makes its technology critical for drug discovery, translational research, and fundamental biological studies in oncology, neurology, and cardiology.
Latest Market Research Report on Preclinical Imaging Download PDF Brochure Now
Revvity, Inc.
Revvity, Inc. is a prominent health science solutions provider that holds a significant position in the preclinical imaging market, having spun out from PerkinElmer’s Life Sciences and Diagnostics segments. Revvity specializes in delivering technologies, expertise, and services that cover the entire spectrum of health science, from discovery to diagnosis. Their preclinical imaging portfolio is distinguished by a focus on optical and structural imaging. Key product lines include the IVIS Spectrum series for in vivo optical imaging (bioluminescence and fluorescence) which is essential for monitoring disease progression and therapeutic response in real-time. They also offer microCT structural imaging solutions like the Quantum GX3, and advanced ultrasound platforms. Revvity’s comprehensive suite of imaging systems, reagents, and data analysis software gives researchers high-throughput and highly sensitive tools, making them a crucial partner for pharmaceutical and biotechnology companies driving innovation in preclinical research and drug development.
FUJIFILM VisualSonics, Inc.
FUJIFILM VisualSonics, Inc., a subsidiary of FUJIFILM Holdings Corporation, is globally recognized for pioneering ultra-high-frequency ultrasound and photoacoustic imaging systems tailored for preclinical research. The company’s flagship Vevo imaging systems allow for real-time, non-invasive visualization of small-animal physiology with exceptional resolution, enabling researchers to accurately characterize biological processes. This technology is widely used in oncology, cardiovascular medicine, and molecular biology studies, providing critical functional and anatomical data. VisualSonics has consistently advanced its multimodal capabilities, exemplified by platforms like the Vevo F2 LAZR-X20, which integrates photoacoustic and ultra-high-frequency ultrasound. By delivering highly detailed, high-resolution imaging that is significantly more accessible and non-invasive than other modalities, FUJIFILM VisualSonics plays a vital role in accelerating the pace of drug discovery and fundamental life science research.
Mediso Ltd.
Mediso Ltd. is a key European player in the medical and preclinical imaging industry, specializing in the development and manufacturing of a wide range of imaging systems. Mediso is particularly renowned for its multi-modality preclinical imaging platforms, such as the nanoScan family, which seamlessly integrates PET (Positron Emission Tomography), SPECT (Single-Photon Emission Computed Tomography), CT, and MRI modalities. These hybrid systems are designed to provide complementary anatomical, functional, and molecular information simultaneously, which is critical for complex translational research. The company also develops integrated software solutions, including InterView™ FUSION, for sophisticated image reconstruction and data analysis. Mediso’s commitment to delivering high-performance, modular, and integrated systems makes it an essential provider for academic institutions, research centers, and pharmaceutical companies requiring versatile and reliable preclinical imaging infrastructure to support drug development and disease modeling.
MILabs B.V.
MILabs B.V., now a Rigaku company, is a global leader in molecular imaging, distinguished by its development of high-performance preclinical micro-PET, micro-SPECT, micro-CT, and Optical Tomography systems. The company is particularly known for its proprietary U-SPECT technology, which provides ultra-high resolution and sensitivity for single-photon emission computed tomography, a significant advantage in tracing molecular processes in small animals. MILabs focuses on enhancing research accuracy and productivity by offering unique, adaptive, and high-resolution systems that are often integrated onto a single multi-modal platform. The user-friendly operation and integrated workflow of their systems are designed to maximize efficiency in oncology, neurology, and pharmacology research. By consistently delivering cutting-edge, award-winning technology, MILabs maintains a leading position in the specialized segment of high-fidelity molecular preclinical imaging.
Siemens Healthineers AG
Siemens Healthineers AG, a major international medical technology company, extends its cutting-edge imaging expertise into the preclinical research domain. Although primarily known for clinical systems, Siemens Healthineers is a key contributor to the preclinical imaging market, particularly through its advanced PET/CT, MRI, and hybrid imaging tools. The company’s focus is on developing high-resolution, high-performance systems that facilitate early disease detection and precision diagnostics, providing a clear translational pathway from preclinical models to clinical application. Their imaging platforms leverage advanced features, including AI algorithms, to improve image clarity and reduce scanning time. By providing sophisticated, reliable, and integrated imaging hardware and digital health platforms, Siemens Healthineers enables researchers to perform complex molecular imaging and drive advancements in precision medicine.
Charles River Laboratories
Charles River Laboratories is a globally diversified contract research organization (CRO) and a leading provider of preclinical services, including comprehensive preclinical imaging and radiochemistry solutions. With extensive experience in drug development, Charles River assists pharmaceutical and biotech partners in making faster go/no-go decisions. Their in vivo preclinical imaging solutions include a variety of modalities such as MicroPET, MicroSPECT, CT, and Quantitative Whole-Body Autoradiography (QWBA) for both small and large animals. They also provide crucial radiochemistry services, including radiolabeling of compounds and tracer development for translational imaging. By offering integrated imaging, data analysis, and regulatory support within IND-enabling programs, Charles River serves as a vital service partner, providing the necessary scientific and technical expertise for complex preclinical development and safety assessment.
Perceptive (Part of ICON)
Perceptive, an ICON company, is a highly trusted provider of imaging and eClinical solutions, spanning the entire drug development lifecycle from preclinical to late-phase clinical trials. In the preclinical imaging space, Perceptive offers comprehensive services and scientific expertise to support discovery research. The company’s offerings include Preclinical Imaging Core Lab services, which provide independent review, data management, and image collection logistics tailored to the specific needs of a study. Perceptive’s value proposition is built on its deep scientific, medical, and technical expertise across various tumor response criteria and imaging modalities. By integrating these specialized imaging services with their broader eClinical and randomization (RTSM) solutions, Perceptive serves as a critical strategic partner, ensuring reliable data outcomes and streamlined operations for worldwide preclinical and clinical trials.
MR Solutions
MR Solutions is an innovative company specializing in the design and manufacture of high-performance Magnetic Resonance Imaging (MRI) systems, with a particular focus on the preclinical sector. The company is renowned for pioneering the development of cryogen-free MRI systems, a technological breakthrough that significantly reduces running costs and eliminates the need for liquid helium, making the technology more accessible to research institutions. MR Solutions offers a range of high-field MRI scanners that deliver superior soft tissue contrast and high-resolution anatomical and functional images essential for preclinical research in oncology and neurology. Furthermore, the company focuses on multi-modality integration, providing seamless combinations of MRI with PET or SPECT. Their commitment to developing compact, versatile, and cost-effective MRI technology for in vivo imaging solidifies their position as a key innovator in the specialized preclinical imaging market.
Agilent Technologies
Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and chemical analysis, with a significant role in the preclinical research ecosystem through its advanced instrumentation and solutions. While Agilent’s portfolio is broad, its contributions to preclinical imaging are focused on enhancing the analytical workflow and data quality, particularly in areas surrounding sample preparation and molecular analysis that complement imaging studies. Agilent provides instruments and consumables for molecular and high-content imaging applications. Their Bioanalyzer kits, for example, are crucial for the quality control of nucleic acids and proteins used in imaging-based assays. By supplying the high-quality analytical backbone for life science research and continually advancing its instrumentation, Agilent empowers researchers to achieve high-fidelity data in their preclinical studies, supporting drug discovery and disease research with robust and reliable analytical solutions.
Latest Market Research Report on Preclinical Imaging Download PDF Brochure Now